<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459957</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Differences in Susceptibility to SARS-CoV-2 Infection Among Transgenic hACE2-Hamster Founder Lines.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1625</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101625</ELocationID><Abstract><AbstractText>Animal models that are susceptible to SARS-CoV-2 infection and develop clinical signs like human COVID-19 are desired to understand viral pathogenesis and develop effective medical countermeasures. The golden Syrian hamster is important for the study of SARS-CoV-2 since hamsters are naturally susceptible to SARS-CoV-2. However, infected hamsters show only limited clinical disease and resolve infection quickly. In this study, we describe development of human angiotensin-converting enzyme 2 (hACE2) transgenic hamsters as a model for COVID-19. During development of the model for SARS-CoV-2, we observed that different hACE2 transgenic hamster founder lines varied in their susceptibility to SARS-CoV-2 lethal infection. The highly susceptible hACE2 founder lines F0F35 and F0M41 rapidly progress to severe infection and death within 6 days post-infection (p.i.). Clinical signs included lethargy, weight loss, dyspnea, and mortality. Lethality was observed in a viral dose-dependent manner with a lethal dose as low as 1 × 10<sup>0.15</sup> CCID<sub>50</sub>. In addition, virus shedding from highly susceptible lines was detected in oropharyngeal swabs on days 2-5 p.i., and virus titers were observed at 10<sup>5.5-6.5</sup> CCID<sub>50</sub> in lung and brain tissue by day 4 p.i.. Histopathology revealed that infected hACE2-hamsters developed rhinitis, tracheitis, bronchointerstitial pneumonia, and encephalitis. Mortality in highly susceptible hACE2-hamsters can be attributed to neurologic disease with contributions from the accompanying respiratory disease. In contrast, virus challenge of animals from less susceptible founder lines, F0M44 and F0M51, resulted in only 0-20% mortality. To demonstrate utility of this SARS-CoV-2 infection model, we determined the protective effect of the TLR3 agonist polyinosinic-polycytidylic acid (Poly (I:C)). Prophylactic treatment with Poly (I:C) significantly improved survival in highly susceptible hACE2-hamsters. In summary, our studies demonstrate that hACE2 transgenic hamsters differ in their susceptibility to SARS-CoV-2 infection, based on the transgenic hamster founder line, and that prophylactic treatment with Poly (I:C) was protective in this COVID-19 model of highly susceptible hACE2-hamsters.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yanan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurst</LastName><ForeName>Brett L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0003-1025-5878</Identifier><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddharthan</LastName><ForeName>Venkatraman</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Deanna P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheesley</LastName><ForeName>Ashley Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Rebekah</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunzler</LastName><ForeName>Madelyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polejaeva</LastName><ForeName>Irina A</ForeName><Initials>IA</Initials><Identifier Source="ORCID">0000-0002-0858-5889</Identifier><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Wettere</LastName><ForeName>Arnaud J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-9611-1316</Identifier><AffiliationInfo><Affiliation>Department of Veterinary, Clinical, and Life Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Utah Veterinary Diagnostic Laboratory, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moisyadi</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5320-4133</Identifier><AffiliationInfo><Affiliation>Institute of Biogenesis Research, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96822, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrey</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarbet</LastName><ForeName>E Bart</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0002-4255-9094</Identifier><AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterinary, Clinical, and Life Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhongde</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-2441-4729</Identifier><AffiliationInfo><Affiliation>Department of Animal, Diary and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN272201700041I, Task Order 75N93020F00001</GrantID><Agency>Contract number HHSN272201700041I, Task Order 75N93020F00001, Task A38, from the Virology Branch, DMID, NIAID, NIH</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008647" MajorTopicYN="N">Mesocricetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">animal model</Keyword><Keyword MajorTopicYN="N">transgenic hamster</Keyword><Keyword MajorTopicYN="N">viral pathogenesis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459957</ArticleId><ArticleId IdType="pmc">PMC11512293</ArticleId><ArticleId IdType="doi">10.3390/v16101625</ArticleId><ArticleId IdType="pii">v16101625</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ollarves-Carrero M.F., Rodriguez-Morales A.G., Bonilla-Aldana D.K., Rodriguez-Morales A.J. Anosmia in a Healthcare Worker with COVID-19 in Madrid, Spain. Travel Med. Infect. Dis. 2020;35:101666. doi: 10.1016/j.tmaid.2020.101666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101666</ArticleId><ArticleId IdType="pmc">PMC7194729</ArticleId><ArticleId IdType="pubmed">32298782</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M., Kedzierska K. A Race to Determine What Drives COVID-19 Severity. Nature. 2020;583:366–368. doi: 10.1038/d41586-020-01915-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-01915-3</ArticleId><ArticleId IdType="pubmed">32661414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemele D., Ķauķe G., Skrējāne K., Jaunozoliņa L., Karelis G. A Fatal Case of COVID-19-Associated Acute Necrotizing Encephalopathy. Eur. J. Neurol. 2021;28:3870–3872. doi: 10.1111/ene.14966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14966</ArticleId><ArticleId IdType="pmc">PMC8653160</ArticleId><ArticleId IdType="pubmed">34655265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Tan Y., Ling Y., Lu G., Liu F., Yi Z., Jia X., Wu M., Shi B., Xu S., et al. Viral and Host Factors Related to the Clinical Outcome of COVID-19. Nature. 2020;583:437–440. doi: 10.1038/s41586-020-2355-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2355-0</ArticleId><ArticleId IdType="pubmed">32434211</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G., Townsend L., Savinelli S., Mallon P.W.G., Kenny G. Long COVID: Clinical Characteristics, Proposed Pathogenesis and Potential Therapeutic Targets. Front. Mol. Biosci. 2023;10:1157651. doi: 10.3389/fmolb.2023.1157651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2023.1157651</ArticleId><ArticleId IdType="pmc">PMC10171433</ArticleId><ArticleId IdType="pubmed">37179568</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig A.M. Deleterious Outcomes in Long-Hauler COVID-19: The Effects of SARS-CoV-2 on the CNS in Chronic COVID Syndrome. ACS Chem. Neurosci. 2020;11:4017–4020. doi: 10.1021/acschemneuro.0c00725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00725</ArticleId><ArticleId IdType="pubmed">33275404</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha N.K., Ojha S., Jha S.K., Dureja H., Singh S.K., Shukla S.D., Chellappan D.K., Gupta G., Bhardwaj S., Kumar N., et al. Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations. J. Mol. Neurosci. 2021;71:2192–2209. doi: 10.1007/s12031-020-01767-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-020-01767-6</ArticleId><ArticleId IdType="pmc">PMC7814864</ArticleId><ArticleId IdType="pubmed">33464535</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson R.W., Brown R.L., Benjamin L., Nortley R., Wiethoff S., Bharucha T., Jayaseelan D.L., Kumar G., Raftopoulos R.E., Zambreanu L., et al. The Emerging Spectrum of COVID-19 Neurology: Clinical, Radiological and Laboratory Findings. Brain. 2020;143:3104–3120. doi: 10.1093/brain/awaa240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa240</ArticleId><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyiadji N., Shahin G., Noujaim D., Stone M., Patel S., Griffith B. COVID-19-Associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology. 2020;296:E119–E120. doi: 10.1148/radiol.2020201187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020201187</ArticleId><ArticleId IdType="pmc">PMC7233386</ArticleId><ArticleId IdType="pubmed">32228363</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Geddes J.R., Husain M., Luciano S., Harrison P.J. 6-Month Neurological and Psychiatric Outcomes in 236 379 Survivors of COVID-19: A Retrospective Cohort Study Using Electronic Health Records. Lancet Psychiatry. 2021;8:416–427. doi: 10.1016/S2215-0366(21)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683–690. doi: 10.1001/jamaneurol.2020.1127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Sia S.F., Yan L.M., Chin A.W.H., Fung K., Choy K.T., Wong A.Y.L., Kaewpreedee P., Perera R.A.P.M., Poon L.L.M., Nicholls J.M., et al. Pathogenesis and Transmission of SARS-CoV-2 in Golden Hamsters. Nature. 2020;583:834–838. doi: 10.1038/s41586-020-2342-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2342-5</ArticleId><ArticleId IdType="pmc">PMC7394720</ArticleId><ArticleId IdType="pubmed">32408338</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang R.D., Liu M.Q., Chen Y., Shan C., Zhou Y.W., Shen X.R., Li Q., Zhang L., Zhu Y., Si H.R., et al. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2. Cell. 2020;182:50–58.e8. doi: 10.1016/j.cell.2020.05.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.027</ArticleId><ArticleId IdType="pmc">PMC7241398</ArticleId><ArticleId IdType="pubmed">32516571</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L., Deng W., Huang B., Gao H., Liu J., Ren L., Wei Q., Yu P., Xu Y., Qi F., et al. The Pathogenicity of SARS-CoV-2 in HACE2 Transgenic Mice. Nature. 2020;583:830–833. doi: 10.1038/s41586-020-2312-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2312-y</ArticleId><ArticleId IdType="pubmed">32380511</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F.W., Yuan S., Zhang A.J., Poon V.K.M., Chan C.C.S., Lee A.C.Y., Fan Z., Li C., Liang R., Cao J., et al. Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19) Clin. Infect. Dis. 2020;71:2139–2149. doi: 10.1093/cid/ciaa644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa644</ArticleId><ArticleId IdType="pmc">PMC7314229</ArticleId><ArticleId IdType="pubmed">32472679</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumaki Y., Day C.W., Bailey K.W., Wandersee M.K., Wong M.H., Madsen J.R., Madsen J.S., Nelson N.M., Hoopes J.D., Woolcott J.D., et al. Induction of Interferon-γ-Inducible Protein 10 by SARS-CoV Infection, Interferon Alfacon 1 and Interferon Inducer in Human Bronchial Epithelial Calu-3 Cells and BALB/c Mice. Antivir. Chem. Chemother. 2010;20:169–177. doi: 10.3851/IMP1477.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP1477</ArticleId><ArticleId IdType="pubmed">20231782</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E. Interferon and Its Inducers—A Never-Ending Story: “Old” and “New” Data in a New Perspective. J. Infect. Dis. 2006;194:S19–S26. doi: 10.1086/505351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/505351</ArticleId><ArticleId IdType="pmc">PMC7202558</ArticleId><ArticleId IdType="pubmed">16921467</ArticleId></ArticleIdList></Reference><Reference><Citation>Shashi Bhushan B.L., Wanve S., Koradia P., Bhomia V., Soni P., Chakraborty S., Khobragade A., Joshi S., Mendiratta S.K., Kansagra K.K., et al. Efficacy and Safety of Pegylated Interferon-A2b in Moderate COVID-19: A Phase 3, Randomized, Comparator-Controlled, Open-Label Study. Int. J. Infect. Dis. 2021;111:281–287. doi: 10.1016/j.ijid.2021.08.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.08.044</ArticleId><ArticleId IdType="pmc">PMC8379820</ArticleId><ArticleId IdType="pubmed">34428542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., Péré H., Charbit B., Bondet V., Chenevier-Gobeaux C., et al. Impaired Type I Interferon Activity and Inflammatory Responses in Severe COVID-19 Patients. Science. 2020;369:718–724. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>McCray P.B., Jr., Pewe L., Wohlford-Lenane C., Hickey M., Manzel L., Shi L., Netland J., Jia H.P., Halabi C., Sigmund C.D., et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 2007;81:813–821. doi: 10.1128/JVI.02012-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02012-06</ArticleId><ArticleId IdType="pmc">PMC1797474</ArticleId><ArticleId IdType="pubmed">17079315</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L.J., Muench H. A Simple Method of Estimating Fifty per Cent Endpoints. Am. J. Epidemiol. 1938;27:493–497. doi: 10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals . Guide for the Care and Use of Laboratory Animals. 8th ed. National Academies Press (US); Washington, DC, USA: 2011.</Citation></Reference><Reference><Citation>Fox S.E., Akmatbekov A., Harbert J.L., Li G., Quincy Brown J., Vander Heide R.S. Pulmonary and cardiac pathology in African American patients with COVID-19: An autopsy series from New Orleans. Lancet Respir. Med. 2020;8:681–686. doi: 10.1016/S2213-2600(20)30243-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30243-5</ArticleId><ArticleId IdType="pmc">PMC7255143</ArticleId><ArticleId IdType="pubmed">32473124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cajanding R.J.M. Comprehensive review of cardiovascular involvement in COVID-19. AACN Adv. Crit. Care. 2021;32:169–187. doi: 10.4037/aacnacc2021302.</Citation><ArticleIdList><ArticleId IdType="doi">10.4037/aacnacc2021302</ArticleId><ArticleId IdType="pubmed">33836538</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslbauer J.D., Tzankov A., Mertz K.D., Schwab N., Nienhold R., Twerenbold R., Leibundgut G., Stalder A.K., Matter M., Glatz K. Characterisation of cardiac pathology in 23 autopsies of lethal COVID-19. J. Pathol. Clin. Res. 2021;7:326–337. doi: 10.1002/cjp2.212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cjp2.212</ArticleId><ArticleId IdType="pmc">PMC8185365</ArticleId><ArticleId IdType="pubmed">33837673</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden J.W., Li R., Cline C.R., Zeng X., Mucker E.M., Fuentes-Lao A.J., Spik K.W., Williams J.A., Twenhafel N., Davis N., et al. Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. mBio. 2022;13:e0290621. doi: 10.1128/mbio.02906-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.02906-21</ArticleId><ArticleId IdType="pmc">PMC8787465</ArticleId><ArticleId IdType="pubmed">35073750</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., Takeuchi O., Sugiyama M., Okabe M., Takeda K., et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301:640–643. doi: 10.1126/science.1087262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1087262</ArticleId><ArticleId IdType="pubmed">12855817</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vree P.J., de Wit E., Yilmaz M., van de Heijning M., Klous P., Verstegen M.J., Wan Y., Teunissen H., Krijger P.H., Geeven G., et al. Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. Nat. Biotechnol. 2014;32:1019–1025. doi: 10.1038/nbt.2959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2959</ArticleId><ArticleId IdType="pubmed">25129690</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Z., Bao L., Yu P., Qi F., Gong S., Wang J., Zhao B., Liu M., Han Y., Deng W., et al. SARS-CoV-2 Causes a Systemically Multiple Organs Damages and Dissemination in Hamsters. Front. Microbiol. 2021;11:618891. doi: 10.3389/fmicb.2020.618891.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.618891</ArticleId><ArticleId IdType="pmc">PMC7835519</ArticleId><ArticleId IdType="pubmed">33510731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari P., Rothan H.A., Natekar J.P., Stone S., Pathak H., Strate P.G., Arora K., Brinton M.A., Kumar M. Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-HACE2 Mice. Viruses. 2021;13:132. doi: 10.3390/v13010132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010132</ArticleId><ArticleId IdType="pmc">PMC7832889</ArticleId><ArticleId IdType="pubmed">33477869</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhaleva L.M., Cherniaev A.L., Samsonova M.V., Zayratyants O.V., Kakturskiy L.V., Vasyukova O.A., Birukov A.E., Kontorshchikov A.S., Sorokina A.V., Sinelnikov M.Y. Pathological Features in 100 Deceased Patients with COVID-19 in Correlation with Clinical and Laboratory Data. Pathol. Oncol. Res. 2021;27:1609900. doi: 10.3389/pore.2021.1609900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/pore.2021.1609900</ArticleId><ArticleId IdType="pmc">PMC8376972</ArticleId><ArticleId IdType="pubmed">34421396</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun P., Qie S., Liu Z., Ren J., Li K., Xi J. Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 Infection: A Single Arm Meta-Analysis. J. Med. Virol. 2020;92:612–617. doi: 10.1002/jmv.25735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25735</ArticleId><ArticleId IdType="pmc">PMC7228255</ArticleId><ArticleId IdType="pubmed">32108351</ArticleId></ArticleIdList></Reference><Reference><Citation>Synowiec A., Szczepa A., Barreto-Duran E., Lie L.K., Pyrc K. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Systemic Infection. Clin. Microbiol. Rev. 2021;34:e00133-20. doi: 10.1128/CMR.00133-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00133-20</ArticleId><ArticleId IdType="pmc">PMC7849242</ArticleId><ArticleId IdType="pubmed">33441314</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau G.B., Burgess S.L., Sturek J.M., Donlan A.N., Petri W.A., Mann B.J. Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection. Am. J. Trop. Med. Hyg. 2020;103:1215–1219. doi: 10.4269/ajtmh.20-0762.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0762</ArticleId><ArticleId IdType="pmc">PMC7470527</ArticleId><ArticleId IdType="pubmed">32723427</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber A.D., Firsching T.C., Trimpert J., Dietert K. Hamster models of COVID-19 pneumonia reviewed: How human can they be? Vet. Pathol. 2021;59:528–545. doi: 10.1177/03009858211057197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03009858211057197</ArticleId><ArticleId IdType="pmc">PMC9207993</ArticleId><ArticleId IdType="pubmed">34856819</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong Y., Lee J.H., Perry D.L., Cooper K., Wang H., Dixit S., Liu D.X., Feuerstein I.M., Solomon J., Bartos C., et al. Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models. Antivir. Res. 2023;214:105605. doi: 10.1016/j.antiviral.2023.105605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2023.105605</ArticleId><ArticleId IdType="pmc">PMC10105383</ArticleId><ArticleId IdType="pubmed">37068595</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhowmick S., Drew K.L. Mechanisms of innate preconditioning towards ischemia/anoxia tolerance: Lessons from mammalian hibernators. Cond. Med. 2019;2:134–141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7295161</ArticleId><ArticleId IdType="pubmed">32542230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi F., Pretto S., Tagliabue E., Balsari A., Sfondrini L. Exploiting poly(I:C) to induce cancer cell apoptosis. Cancer Biol. Ther. 2017;18:747–756. doi: 10.1080/15384047.2017.1373220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384047.2017.1373220</ArticleId><ArticleId IdType="pmc">PMC5678690</ArticleId><ArticleId IdType="pubmed">28881163</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann P.J., Iida S., Iwatsuki-Horimoto K., Maemura T., Kiso M., Scheaffer S.M., Darling T.L., Joshi A., Loeber S., Singh G., et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature. 2022;603:687–692. doi: 10.1038/s41586-022-04441-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04441-6</ArticleId><ArticleId IdType="pmc">PMC8942849</ArticleId><ArticleId IdType="pubmed">35062015</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R., Kiso M., Iida S., Imai M., Takashita E., Kuroda M., Halfmann P.J., Loeber S., Maemura T., Yamayoshi S., et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022;607:119–127. doi: 10.1038/s41586-022-04856-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04856-1</ArticleId><ArticleId IdType="pmc">PMC10579982</ArticleId><ArticleId IdType="pubmed">35576972</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R., Halfmann P.J., Iida S., Yamayoshi S., Furusawa Y., Kiso M., Ito M., Iwatsuki-Horimoto K., Mine S., Kuroda M., et al. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature. 2022;612:540–545. doi: 10.1038/s41586-022-05482-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05482-7</ArticleId><ArticleId IdType="pubmed">36323336</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R., Iida S., Halfmann P.J., Yamayoshi S., Hirata Y., Iwatsuki-Horimoto K., Kiso M., Ito M., Furusawa Y., Ueki H., et al. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. Nat. Commun. 2023;14:1620. doi: 10.1038/s41467-023-37059-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37059-x</ArticleId><ArticleId IdType="pmc">PMC10035475</ArticleId><ArticleId IdType="pubmed">36959194</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann P.J., Iwatsuki-Horimoto K., Kuroda M., Hirata Y., Yamayoshi S., Iida S., Uraki R., Ito M., Ueki H., Furusawa Y., et al. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters. Commun. Biol. 2024;7:331. doi: 10.1038/s42003-024-06015-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-024-06015-w</ArticleId><ArticleId IdType="pmc">PMC10943235</ArticleId><ArticleId IdType="pubmed">38491227</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilliland T., Dunn M., Liu Y., Alcorn M.D.H., Terada Y., Vasilatos S., Lundy J., Li R., Nambulli S., Larson D., et al. Transchromosomic bovine-derived anti-SARS-CoV-2 polyclonal human antibodies protects hACE2 transgenic hamsters against multiple variants. iScience. 2023;26:107764. doi: 10.1016/j.isci.2023.107764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.107764</ArticleId><ArticleId IdType="pmc">PMC10509298</ArticleId><ArticleId IdType="pubmed">37736038</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(− Delta Delta C(T)) Method. Methods. 2001;25:402. doi: 10.1006/meth.2001.1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivcec M., Safronetz D., Haddock E., Feldmann H., Ebihara H. Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus) J. Immunol. Methods. 2011;368:24–35. doi: 10.1016/j.jim.2011.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2011.02.004</ArticleId><ArticleId IdType="pmc">PMC3085612</ArticleId><ArticleId IdType="pubmed">21334343</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>